Targeting GITR in Cancer Immunotherapy - There is No Perfect Knowledge

Overview

Journal Oncotarget

Specialty Oncology

Date 2023 Jun 19

PMID 37335294

Authors

Diwakar Davar

Roberta Zappasodi

Affiliations

Soon will be listed here.

Abstract

Glucocorticoid-induced TNFR-related protein (GITR) belongs to the TNFR superfamily (TNFRSF) and stimulates both the acquired and innate immunity. GITR is broadly expressed on immune cells, particularly regulatory T cells (Tregs) and natural killer (NK) cells. Given its potential to promote T effector function and impede Treg immune suppression, GITR is an attractive target for cancer immunotherapy. Preclinically, GITR agonists have demonstrated potent anti-tumor efficacy singly and in combination with a variety of agents, including PD-1 blockade. Multiple GITR agonists have been advanced into the clinic, although the experience with these agents has been disappointing. Recent mechanistic insights into the roles of antibody structure, valency, and Fc functionality in mediating anti-tumor efficacy may explain some of the apparent inconsistency or discordance between preclinical data and observed clinical efficacy.

Citing Articles

Tumor Microenvironment Drives the Cross-Talk Between Co-Stimulatory and Inhibitory Molecules in Tumor-Infiltrating Lymphocytes: Implications for Optimizing Immunotherapy Outcomes.

Franzese O Int J Mol Sci. 2024; 25(23).

PMID: 39684559 PMC: 11641238. DOI: 10.3390/ijms252312848.

Targeting the TNF and TNFR superfamilies in autoimmune disease and cancer.

Croft M, Salek-Ardakani S, Ware C Nat Rev Drug Discov. 2024; 23(12):939-961.

PMID: 39448880 DOI: 10.1038/s41573-024-01053-9.

Tumor necrosis factor superfamily signaling: life and death in cancer.

Ababneh O, Nishizaki D, Kato S, Kurzrock R Cancer Metastasis Rev. 2024; 43(4):1137-1163.

PMID: 39363128 PMC: 11554763. DOI: 10.1007/s10555-024-10206-6.

Exploring the Role of GITR/GITRL Signaling: From Liver Disease to Hepatocellular Carcinoma.

Papadakos S, Chatzikalil E, Vakadaris G, Reppas L, Arvanitakis K, Koufakis T Cancers (Basel). 2024; 16(14).

PMID: 39061246 PMC: 11275207. DOI: 10.3390/cancers16142609.

Transcriptomic analysis of GITR and GITR ligand reveals cancer immune heterogeneity with implications for GITR targeting.

Moussa P, Kurzrock R, Nishizaki D, Miyashita H, Lee S, Nikanjam M Am J Cancer Res. 2024; 14(4):1634-1648.

PMID: 38726288 PMC: 11076267. DOI: 10.62347/ECED5481.

References

Xie P . TRAF molecules in cell signaling and in human diseases. J Mol Signal. 2013; 8(1):7. PMC: 3697994. DOI: 10.1186/1750-2187-8-7. View

Park H . Structure of TRAF Family: Current Understanding of Receptor Recognition. Front Immunol. 2018; 9:1999. PMC: 6125299. DOI: 10.3389/fimmu.2018.01999. View

Bulliard Y, Jolicoeur R, Windman M, Rue S, Ettenberg S, Knee D . Activating Fc γ receptors contribute to the antitumor activities of immunoregulatory receptor-targeting antibodies. J Exp Med. 2013; 210(9):1685-93. PMC: 3754864. DOI: 10.1084/jem.20130573. View

Zappasodi R, Sirard C, Li Y, Budhu S, Abu-Akeel M, Liu C . Rational design of anti-GITR-based combination immunotherapy. Nat Med. 2019; 25(5):759-766. PMC: 7457830. DOI: 10.1038/s41591-019-0420-8. View

Eck M, Sprang S . The structure of tumor necrosis factor-alpha at 2.6 A resolution. Implications for receptor binding. J Biol Chem. 1989; 264(29):17595-605. DOI: 10.2210/pdb1tnf/pdb. View

Papadopoulos K, Autio K, Golan T, Dobrenkov K, Chartash E, Chen Q . Phase I Study of MK-4166, an Anti-human Glucocorticoid-Induced TNF Receptor Antibody, Alone or with Pembrolizumab in Advanced Solid Tumors. Clin Cancer Res. 2020; 27(7):1904-1911. PMC: 9094061. DOI: 10.1158/1078-0432.CCR-20-2886. View

Cohen A, Schaer D, Liu C, Li Y, Hirschhorn-Cymmerman D, Kim S . Agonist anti-GITR monoclonal antibody induces melanoma tumor immunity in mice by altering regulatory T cell stability and intra-tumor accumulation. PLoS One. 2010; 5(5):e10436. PMC: 2862699. DOI: 10.1371/journal.pone.0010436. View

Krausz L, Bianchini R, Ronchetti S, Fettucciari K, Nocentini G, Riccardi C . GITR-GITRL system, a novel player in shock and inflammation. ScientificWorldJournal. 2007; 7:533-66. PMC: 5901298. DOI: 10.1100/tsw.2007.106. View

McHugh R, Whitters M, Piccirillo C, Young D, Shevach E, Collins M . CD4(+)CD25(+) immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid-induced TNF receptor. Immunity. 2002; 16(2):311-23. DOI: 10.1016/s1074-7613(02)00280-7. View

10.

Snell L, McPherson A, Lin G, Sakaguchi S, Pandolfi P, Riccardi C . CD8 T cell-intrinsic GITR is required for T cell clonal expansion and mouse survival following severe influenza infection. J Immunol. 2010; 185(12):7223-34. DOI: 10.4049/jimmunol.1001912. View

11.

Villarreal D, Chin D, Smith M, Luistro L, Snyder L . Combination GITR targeting/PD-1 blockade with vaccination drives robust antigen-specific antitumor immunity. Oncotarget. 2017; 8(24):39117-39130. PMC: 5503599. DOI: 10.18632/oncotarget.16605. View

12.

Stephens G, McHugh R, Whitters M, Young D, Luxenberg D, Carreno B . Engagement of glucocorticoid-induced TNFR family-related receptor on effector T cells by its ligand mediates resistance to suppression by CD4+CD25+ T cells. J Immunol. 2004; 173(8):5008-20. DOI: 10.4049/jimmunol.173.8.5008. View

13.

Amoozgar Z, Kloepper J, Ren J, Tay R, Kazer S, Kiner E . Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas. Nat Commun. 2021; 12(1):2582. PMC: 8113440. DOI: 10.1038/s41467-021-22885-8. View

14.

Nocentini G, Riccardi C . GITR: a modulator of immune response and inflammation. Adv Exp Med Biol. 2009; 647:156-73. DOI: 10.1007/978-0-387-89520-8_11. View

15.

Croft M . The role of TNF superfamily members in T-cell function and diseases. Nat Rev Immunol. 2009; 9(4):271-85. PMC: 2737409. DOI: 10.1038/nri2526. View

16.

Mahne A, Mauze S, Joyce-Shaikh B, Xia J, Bowman E, Beebe A . Dual Roles for Regulatory T-cell Depletion and Costimulatory Signaling in Agonistic GITR Targeting for Tumor Immunotherapy. Cancer Res. 2017; 77(5):1108-1118. DOI: 10.1158/0008-5472.CAN-16-0797. View

17.

Chan F, Chun H, Zheng L, Siegel R, Bui K, Lenardo M . A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling. Science. 2000; 288(5475):2351-4. DOI: 10.1126/science.288.5475.2351. View

18.

Chen L, Flies D . Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013; 13(4):227-42. PMC: 3786574. DOI: 10.1038/nri3405. View

19.

Ko K, Yamazaki S, Nakamura K, Nishioka T, Hirota K, Yamaguchi T . Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med. 2005; 202(7):885-91. PMC: 2213162. DOI: 10.1084/jem.20050940. View

20.

Nishikawa H, Kato T, Hirayama M, Orito Y, Sato E, Harada N . Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Cancer Res. 2008; 68(14):5948-54. DOI: 10.1158/0008-5472.CAN-07-5839. View